RNAi agents for inhibiting expression of microtubule associated protein tau (MAPT), compositions thereof, and methods of use
Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of a microtubule associated protein tau (MAPT) gene. The MAPT RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of a MAPT gene. The MAPT RNAi agents are conjugated to an antigen binding protein that may enable subcutaneous delivery of the RNAi agents by facilitating crossing of the blood brain barrier (BBB). Pharmaceutical compositions that include one or more MAPT RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described MAPT RNAi agents to central nervous system (CNS) tissue, in vivo, provides for inhibition of MAPT gene expression and a reduction in MAPT activity, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases including Alzheimer's disease, Frontotemporal lobar degeneration dementia (FTLD), Progressive supranuclear palsy, and other tauopathies.
1 . An RNAi agent for inhibiting expression of a microtubule associated protein tau (MAPT) gene, comprising:
an antisense strand consisting of the nucleotide sequence
cPrpusAfsgucuAfccauGfuCfgAfugcussg (SEQ ID NO: 592), wherein a represents 2′-O-methyl adenosine, c represents 2′-O-methyl cytidine, g represents 2′-O-methyl guanosine, u represents 2′-O-methyl uridine; Af represents 2′-fluoro adenosine, Cf represents 2′-fluoro cytidine, Gf represents 2′-fluoro guanosine, Uf represents 2′-fluoro uridine; cPrpu represents 5′-cyclopropyl phosphonate-2′-O-methyl uridine; s represents a phosphorothioate linkage; and ss represents a phosphorodithioate linkage; and
a sense strand comprising a nucleotide sequence that is at least partially complementary to the antisense strand;
wherein all of the nucleotides of the sense strand are modified nucleotides.
2 . The RNAi agent of claim 1 , wherein all or substantially all of the nucleotides of the sense strand are modified with 2′-O-methyl nucleotides, 2′-fluoro nucleotides, or combinations thereof.
3 . The RNAi agent of claim 1 , wherein the sense strand is 18 to 30 nucleotides in length.
4 . The RNAi agent of claim 1 , wherein the sense strand is 21 nucleotides in length.
5 . The RNAi agent of claim 1 , wherein the sense strand comprises one or two terminal caps.
6 . The RNAi agent of claim 1 , wherein the sense strand comprises one or two inverted abasic residues.
7 . The RNAi agent of claim 1 , wherein the sense strand comprises a nucleotide sequence of one of the following nucleotide sequences (5′→3′):
(SEQ ID NO: 540)
GCAUCGACAUGGUAGACUA;
or
(SEQ ID NO: 777)
CAGCAUCGACAUGGUAGACUA.
8 . The RNAi agent of claim 1 , wherein the sense strand comprises the nucleotide sequence (5′→3′):
cagcaucgAfcAfUfgguagacua (SEQ ID NO: 598);
wherein a represents 2′-O-methyl adenosine, c represents 2′-O-methyl cytidine, g represents 2′-O-methyl guanosine, u represents 2′-O-methyl uridine; Af represents 2′-fluoro adenosine, Cf represents 2′-fluoro cytidine, Gf represents 2′-fluoro guanosine, and Uf represents 2′-fluoro uridine.
9 . The RNAi agent of claim 1 , wherein the RNAi agent is linked to an antigen binding protein.
10 . The RNAi agent of claim 9 , wherein the antigen binding protein is an antibody fragment (Fab), wherein the Fab specifically binds to one or more epitopes on a transferrin receptor (TfR1).
11 . The RNAi agent of claim 10 , wherein the Fab comprises (i) 6 complementary determining regions (CDRs), (ii) 3 CDRs on the variable light chain (VL), and (iii) 3 CDRs on the variable heavy chain (VH).
12 . The RNAi agent of claim 11 , wherein the variable light chain has a VL CDR1 sequence selected from the group consisting of: RASDGLYSNLA (SEQ ID NO: 6), RASDNLYRNLA (SEQ ID NO: 7), and RASDKLYSNLA (SEQ ID NO: 8); a VL CDR2 sequence selected from the group consisting of: DATLLAS (SEQ ID NO: 9), DARNLAS (SEQ ID NO: 10), DAFNLAS (SEQ ID NO: 11), DATRLAS (SEQ ID NO: 12), DATKLAS (SEQ ID NO: 13), and DAKNLAS (SEQ ID NO: 14); and/or a VL CDR 3 sequence of QHFWGTPLT (SEQ ID NO: 15).
13 . The RNAi agent of claim 11 , wherein the variable light chain is selected from any one of the VL chains shown in Table A.
14 . The RNAi agent of claim 11 , wherein the variable heavy chain has a VH CDR1 sequence selected from the group consisting of: GYTFNSYWMH (SEQ ID NO: 16), GYTFKSYWMH (SEQ ID NO: 17), GFTFTSYWMH (SEQ ID NO: 18), GYTFTSYWVH (SEQ ID NO: 19), and GYTFTSYWMH (SEQ ID NO: 20), a VH CDR2 sequence selected from the group consisting of: EINPTNGRVNYIEKFKS (SEQ ID NO: 21), EINPTNGRFNYIEKFKS (SEQ ID NO: 22), EINPTNGRTNYIEKFKS (SEQ ID NO: 23), and EINPTNGRSNYIEKFKS (SEQ ID NO: 24); and/or a VH CDR3 sequence of: GTRAYHY (SEQ ID NO: 25).
15 . The RNAi agent of claim 11 , wherein the variable heavy chain is selected from any one of the VH chains shown in Table B.
16 . The RNAi agent of claim 9 , wherein the antigen binding protein is linked to the 5′ end of the sense strand.
17 . The RNAi agent of claim 1 , wherein the RNAi agent comprises a sense strand selected from the group consisting of:
(SEQ ID NO: 694)
LP310-(NH-C6)s(invAb)scagcaucgAfcAfUfgguagacuas
(invAb);
(SEQ ID NO: 696)
LP462-(NH-C6)s(invAb)scagcaucgAfcAfUfgguagacuas
(invAb);
(SEQ ID NO: 702)
Fab0070-[CP-1113]-L20-(NH-C6)s(invAb)
scagcaucgAfcAfUfgguagacuas(invAb);
and
(SEQ ID NO: 703)
Fab0070-L-1026-(NH-C6)s(invAb)
scagcaucgAfcAfUfgguagacuas(invAb);
wherein a represents 2′-O-methyl adenosine, c represents 2′-O-methyl cytidine, g represents 2′-O-methyl guanosine, u represents 2′-O-methyl uridine; Af represents 2′-fluoro adenosine, Cf represents 2′-fluoro cytidine, Gf represents 2′-fluoro guanosine, and Uf represents 2′-fluoro uridine, s represents a phosphorothioate linkage, (invAb) represents an inverted abasic nucleotide, LP310 represents the structure:
LP462 represents the structure:
(NH-C6)s represents the structure:
L20 represents the structure:
[CP-1113] represents the structure
present on a cysteine residue of Fab0070, L-1026 represents the structure:
Linkage toward RNAi agent
and Fab0070
represents an antibody fragment having a heavy chain sequence of:
(SEQ ID NO: 5)
EVQLVESGGGLVQPGGSLRLSCATSGFTFTSYWMHWVRQAPGKGLEWVA
EINPTNGRTNYIEKFKSRITLSVDKSKSTVYLQMNSLRAEDTAVYYCAR
GTRAYHYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD
YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
YICNVNHKPSNTKVDKRVEPKSCDKTH,
and an light chain sequence of:
(SEQ ID NO: 3)
DIQLTQSPSSLSASVGDRVTITCRASDKLYSNLAWYQQKPGKAPKLLIY
DATLLASGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQHFWGTPLTF
GQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQ
WKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEV
THQGLSSPVTKSFNRGEC.
18 . A composition comprising the RNAi agent of claim 1 , wherein the composition further comprises a pharmaceutically acceptable excipient.
19 . The composition of claim 18 , wherein the RNAi agent is a sodium salt.
20 . The composition of claim 18 , wherein the pharmaceutically acceptable excipient is water for injection.
21 . A method for inhibiting expression of a MAPT gene in a cell, the method comprising introducing into a cell an effective amount of the RNAi agent of claim 1 .
22 . The method of claim 21 , wherein the cell is within a human subject.
23 . A method of treating one or more symptoms or diseases that are mediated at least in part by MAPT activity and/or MAPT gene expression, the method comprising administering to a human subject in need thereof a therapeutically effective amount of the RNAi agent of claim 1 , wherein the method of treating provides relief from or alleviation of the number, severity, and/or frequency of the one or more symptoms or diseases in the human subject.
24 . The method of claim 23 , wherein the disease is a neurodegenerative disease.
25 . The method of claim 24 , wherein the neurodegenerative disease is selected from the group consisting of Alzheimer's disease, Frontotemporal lobar degeneration dementia (FTLD), Progressive supranuclear palsy, and other tauopathies.
26 . The method of claim 25 , wherein the disease is Alzheimer's disease.